![Frontiers | Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts Frontiers | Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts](https://www.frontiersin.org/files/Articles/505157/fcvm-07-00118-HTML/image_m/fcvm-07-00118-t007.jpg)
Frontiers | Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts
![Frontiers | Platelet Transfusion in Patients With Sepsis and Thrombocytopenia: A Propensity Score-Matched Analysis Using a Large ICU Database Frontiers | Platelet Transfusion in Patients With Sepsis and Thrombocytopenia: A Propensity Score-Matched Analysis Using a Large ICU Database](https://www.frontiersin.org/files/Articles/830177/fmed-09-830177-HTML/image_m/fmed-09-830177-g001.jpg)
Frontiers | Platelet Transfusion in Patients With Sepsis and Thrombocytopenia: A Propensity Score-Matched Analysis Using a Large ICU Database
![Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus | SpringerLink Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-021-05498-0/MediaObjects/125_2021_5498_Figa_HTML.png)
Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus | SpringerLink
![Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study | Lipids in Health and Disease | Full Text Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study | Lipids in Health and Disease | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12944-018-0865-7/MediaObjects/12944_2018_865_Fig1_HTML.png)
Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study | Lipids in Health and Disease | Full Text
![Raised platelet levels in diabetes mellitus complicated with nephropathy - Sterner - 1998 - Journal of Internal Medicine - Wiley Online Library Raised platelet levels in diabetes mellitus complicated with nephropathy - Sterner - 1998 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ad23a23f-0a63-4a7f-9c46-4f81b9814486/joim_349_t1.gif)
Raised platelet levels in diabetes mellitus complicated with nephropathy - Sterner - 1998 - Journal of Internal Medicine - Wiley Online Library
![Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 | Circulation Research Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 | Circulation Research](https://www.ahajournals.org/cms/asset/d7e6b14d-fe32-4ace-bdcf-eca9d3c64902/circresaha.120.317703.fig07.jpg)
Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 | Circulation Research
![Frontiers | Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts Frontiers | Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts](https://www.frontiersin.org/files/Articles/505157/fcvm-07-00118-HTML/image_m/fcvm-07-00118-t001.jpg)
Frontiers | Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts
![Frontiers | Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease Frontiers | Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease](https://www.frontiersin.org/files/Articles/670155/fphar-12-670155-HTML/image_m/fphar-12-670155-g001.jpg)
Frontiers | Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
![Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation | Nature Reviews Cardiology Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation | Nature Reviews Cardiology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41569-020-00469-1/MediaObjects/41569_2020_469_Fig1_HTML.png)
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation | Nature Reviews Cardiology
![JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management](https://pub.mdpi-res.com/jcm/jcm-10-00789/article_deploy/html/images/jcm-10-00789-g001.png?1613479924)
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
![Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies | Cardiovascular Diabetology | Full Text Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-018-0763-3/MediaObjects/12933_2018_763_Fig1_HTML.png)
Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies | Cardiovascular Diabetology | Full Text
![Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial - The Lancet Haematology Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/5249a6d3-5e9b-4a8d-b586-c2c02c0dfa34/gr1.gif)